Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
* Subjects, between the ages of 18 and 64 years inclusive~* Subjects with Generalized Anxiety Disorder (GAD)~* Subjects with insomnia related to GAD.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Escitalopram oxalate 10 mg at bedtime
- 2 (Type: ACTIVE_COMPARATOR): Eszopiclone 3 mg at bedtime

Based on this trial design, predict the completion outcome and termination type (if applicable).